doi: 10.1016/j.ajem.2018.03.022
When you take a GLP-1 medication, you naturally eat less because you feel fuller longer, and food cravings diminish
Semaglutide is a prescription medication originally developed to manage type 2 diabetes, now FDA-approved for medical weight loss under brand names like Wegovy and Ozempic
In post-marketing surveillance, elevated serum triglyceride levels (hypertriglyceridemia), sometimes associated with pancreatitis, have been reported rarely in patients who received tamoxifen
The rats were habituated to kaolin for 5 days before pharmacological testing
FDA-approved semaglutide brands and indications Brand Ozempic (injectable) Approval date December 2017 Indication Type 2 diabetes glycemic control Brand Ozempic (injectable) Approval date January 2020 Indication Cardiovascular risk reduction in T2D Brand Rybelsus (oral tablet) Approval date September 2019 Indication Type 2 diabetes (first oral GLP-1) Brand Wegovy (injectable) Approval date June 2021 Indication Chronic weight management (BMI 30 or 27 with comorbidity) Brand Wegovy (injectable) Approval date March 2024 Indication Cardiovascular risk reduction in adults with obesity and CVD Brand Wegovy (injectable) Approval date August 2025 Indication Non-cirrhotic MASH with F2-F3 fibrosis (ESSENCE) Brand Wegovy oral 25 mg pill Approval date December 2025 Indication Chronic weight management (OASIS 4 basis) Brand Ozempic (injectable) Approval date February 2026 Indication CKD progression in T2D (FLOW basis) Research-grade lyophilized semaglutide from supplier sources is not an FDA-approved drug product and is for research use only
